Phase 2 N=42 A Pilot Study of CC-220 to Treat Systemic Lupus Erythematosus.
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in Part 1 Treatment Phase — 5; 7; 7; 8 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=50 Resuscitative Endocrinology: Single-dose Clinical Uses for Estrogen-Traumatic Hemorrhagic Shock (RESCUE - Shock)
Hemorrhagic Shock
Primary: Survival — 16; 21 participants — p=.252
Phase 2 N=28 Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma
Myeloma
Primary: Primary Myeloma Endpoint — 4; 1; 1; 5 Participants
Phase 2 N=49 A Study of ONTAK and CHOP in Newly Diagnosed, Peripheral T-Cell Lymphoma
Lymphoma, T-Cell, Peripheral
Primary: Summary of All Adverse Events by Frequency in Greater Than 20% of Treated Participants — 63.3; 46.9; 40.8; 40.8 Percentage of participants
Phase 2 N=54 Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)
Atopic Dermatitis (AD)
Primary: Percent Change From Baseline in the Eczema Area Severity Index Score (EASI) to Week 16 — -5.8; -75.2 percent change — p=< 0.0001
Phase 2 N=16 Pemetrexed Disodium in Treating Patients With Stage IV Non-small Cell Lung Cancer and ECOG Performance Status 3
Stage IV Non-Small Cell Lung Cancer
Primary: Change in Quality of Life (QOL), Assessed by the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core-30 (QLQ-C30) and QLQ-Lung…
Phase 2 N=23 A Phase 2 Feasibility Study of Abraxane and Carboplatin in Epithelial Neoplasms of the Uterus
Endometrial Cancer
Primary: Tolerability Measured Completion of Dose Regimen — 16 Participants
Phase 2 N=450 Asian Phase 2 Study for Treatment of Pain Associated With Diabetic Peripheral Neuropathy
Pain · Diabetic Peripheral Neuropathy
Primary: Mean Change in Average Daily Pain Score From Baseline Among Participants Who Received DS5565 for Pain Associated With Diabetic Peripheral Neuropathy — -0.59; -0.71…
Phase 2 N=106 A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemia
Lymphoma · Leukemia, Lymphocytic, Chronic, B-Cell
Primary: Part 1: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 3; 1; 0 Participants
Phase 2 N=1 Autologous Cytomegalovirus (CMV)-Specific Cytotoxic T Cells for Cytomegalovirus (CMV) Reactivation
Leukemia · Lymphoma
Primary: Number of Participants With Non-Relapse Mortality — 0 Participants
Phase 2 N=120 Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients
Colorectal Cancer
Primary: Average Area Under the Curve (AUC) for Numbness/Tingling Over 4 Months — 35.4; 31.5 Units on a scale *days
Phase 2 N=182 Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Adult Giant Cell Glioblastoma · Adult Glioblastoma · Adult Gliosarcoma
Primary: Overall Survival — 25.1; 21.6 percentage of participants — p=0.46
Phase 2 N=100 Clinical Investigation to Evaluate the Hemanext® Oxygen Reduction System - Pivotal Trial
Whole Blood Donation and Leukoreduction
Primary: % of Red Blood Cells With Hemolysis — 0.29; 0.29 % of Red Blood Cells with Hemolysis
Phase 2 N=71 Standard Dose Bevacizumab Versus Low Dose Bevacizumab Plus Lomustine (CCNU) for Recurrent Glioblastoma Multiforme (GBM)
Brain Cancer · Glioblastoma
Primary: Progression Free Survival (PFS) — 4.11; 4.34 months
Phase 2 N=133 A Study of Prexasertib (LY2606368) in Participants With Extensive Stage Disease Small Cell Lung Cancer
Small Cell Lung Cancer
Primary: Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]) — 5.2; 0; 0 percentage of participants